CA2856329A1 - Compositions and methods for treating glioma - Google Patents

Compositions and methods for treating glioma Download PDF

Info

Publication number
CA2856329A1
CA2856329A1 CA2856329A CA2856329A CA2856329A1 CA 2856329 A1 CA2856329 A1 CA 2856329A1 CA 2856329 A CA2856329 A CA 2856329A CA 2856329 A CA2856329 A CA 2856329A CA 2856329 A1 CA2856329 A1 CA 2856329A1
Authority
CA
Canada
Prior art keywords
peptide
csf
seq
glioma
set forth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2856329A
Other languages
English (en)
French (fr)
Inventor
Bozena Kaminska-Kaczmarek
Malgorzata Sielska
Pawel Wisniewski
Aleksandra Ellert-Miklaszewska
Original Assignee
NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY
Glia Sp zoo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY, Glia Sp zoo filed Critical NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY
Publication of CA2856329A1 publication Critical patent/CA2856329A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA2856329A 2011-11-17 2012-11-18 Compositions and methods for treating glioma Abandoned CA2856329A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161561080P 2011-11-17 2011-11-17
US61/561,080 2011-11-17
US201261583745P 2012-01-06 2012-01-06
US61/583,745 2012-01-06
PCT/IB2012/056533 WO2013072901A2 (en) 2011-11-17 2012-11-18 Compositions and methods for treating glioma

Publications (1)

Publication Number Publication Date
CA2856329A1 true CA2856329A1 (en) 2013-05-23

Family

ID=47358252

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2856329A Abandoned CA2856329A1 (en) 2011-11-17 2012-11-18 Compositions and methods for treating glioma

Country Status (7)

Country Link
US (2) US9453050B2 (https=)
EP (1) EP2780363B1 (https=)
JP (1) JP6426001B2 (https=)
KR (1) KR20140103122A (https=)
CA (1) CA2856329A1 (https=)
IL (1) IL232648B (https=)
WO (1) WO2013072901A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201220573D0 (en) 2012-11-15 2013-01-02 Univ Central Lancashire Methods of diagnosing proliferative disorders
DE102014207498A1 (de) * 2014-04-17 2015-10-22 Universitätsklinikum Hamburg-Eppendorf Viraler Vektor für den zielgerichteten Gentransfer in Gehirn und Rückenmark
SG11201702475VA (en) * 2014-09-26 2017-04-27 Univ Singapore Methods and compositions for modulating th-gm cell function
US11078264B2 (en) 2018-10-17 2021-08-03 University Of Connecticut Inhibiting granulocyte macrophage-colony stimulating factor (GM-CSF) prevents preterm birth
WO2020110117A1 (en) * 2018-11-28 2020-06-04 Glia Sp. Z O.O. Compositions and methods for treating glioma
CN112007142B (zh) * 2019-05-31 2025-04-22 生物蚕茧研究所股份有限公司 向抗炎m2表型小胶质细胞的极性转化促进剂
PL441229A1 (pl) * 2022-05-19 2023-11-20 Instytut Biologii Doświadczalnej im. Marcelego Nenckiego Polska Akademia Nauk Zaprojektowane, syntetyczne peptydy, zawierające je kompozycje i sposoby ich zastosowania w leczeniu glejaków złośliwych
KR102899196B1 (ko) * 2023-01-20 2025-12-12 (주) 넥셀 치주염 및 임플란트 주변염 예방 또는 치료용 재조합 단백질 및 이를 포함하는 치주염 및 임플란트 주변염 예방 또는 치료용 조성물
CN116650650A (zh) * 2023-06-12 2023-08-29 郑州大学 一种抑制食管鳞癌中肿瘤相关巨噬细胞浸润的方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
AU630496B2 (en) * 1989-07-14 1992-10-29 Schering Corporation Antagonists of gm-csf derived from the carboxyl terminus
WO1991002063A1 (en) * 1989-08-11 1991-02-21 Amrad Corporation Limited Improvements in granulocyte-macrophage colony-stimulating factor receptor and derivatives thereof
AUPN780096A0 (en) * 1996-01-30 1996-02-22 Medvet Science Pty. Ltd. Cytokine antagonists and agonists
US5837231A (en) * 1996-06-27 1998-11-17 Regents Of The University Of Minnesota GM-CSF administration for the treatment and prevention of recurrence of brain tumors
US6372720B1 (en) 1998-02-05 2002-04-16 Kenneth J. Longmuir Liposome fusion and delivery vehicle
CA2288680A1 (en) 1998-11-12 2000-05-12 Jcr Pharmaceuticals Co., Ltd. Modulation of cell proliferative disorders by cyclic rgd
US6551990B2 (en) * 1998-12-07 2003-04-22 University Of Washington Methods of inhibiting ectopic calcification
BR9916536A (pt) 1998-12-23 2002-01-02 Searle & Co Método para o tratamento ou prevenção de um distúrbio de neoplasia em um mamìfero em necessidade deste tratamento ou prevenção, e, combinação
US6521593B1 (en) 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
WO2001074855A2 (en) * 2000-03-30 2001-10-11 Dendreon Corporation Compositions and methods for dendritic cell-based immunotherapy
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
US7063860B2 (en) 2001-08-13 2006-06-20 University Of Pittsburgh Application of lipid vehicles and use for drug delivery
WO2004018498A2 (en) * 2002-05-10 2004-03-04 Children's Medical Center Corporation Minicell display and products therefrom
WO2006087579A1 (en) * 2005-02-18 2006-08-24 Proximagen Ltd. Treatment for neurodegeneration
EP2377884A1 (en) * 2005-05-10 2011-10-19 Neoloch Aps Neuritogenic peptides
WO2007035843A2 (en) * 2005-09-21 2007-03-29 Dask Technologies, Llc Methods and compositions for organ and tissue functionality
AU2007207465B2 (en) 2006-01-18 2012-12-06 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
PL1999152T3 (pl) * 2006-03-27 2013-05-31 Medimmune Ltd Element wiążący receptor GM-CSF
DK2121586T3 (en) 2007-03-09 2017-06-19 Pathologica Llc MGBG FOR THE REGULATION OF OSTEOPONTIN AND THE TREATMENT OF MULTIPLE SCLEROSIS
ES2538362T3 (es) 2007-10-16 2015-06-19 Ventana Medical Systems, Inc. Clasificación, estadificación y pronóstico del cáncer mediante el uso de osteopontina-C
WO2009094172A2 (en) * 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
CN102223915A (zh) 2008-11-20 2011-10-19 默克专利有限公司 应用整联蛋白配体治疗癌症的新疗法和药物
NZ597339A (en) 2009-05-25 2013-10-25 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
BR112012027745A2 (pt) * 2010-04-27 2017-01-10 Univ Johns Hopkins método e composição imunogênica para tratamento de neoplásia

Also Published As

Publication number Publication date
EP2780363A2 (en) 2014-09-24
KR20140103122A (ko) 2014-08-25
US20140256628A1 (en) 2014-09-11
US20170035851A1 (en) 2017-02-09
EP2780363B1 (en) 2019-07-03
JP6426001B2 (ja) 2018-11-21
JP2014533681A (ja) 2014-12-15
IL232648B (en) 2021-12-01
WO2013072901A2 (en) 2013-05-23
WO2013072901A3 (en) 2013-07-25
US9453050B2 (en) 2016-09-27
IL232648A0 (en) 2014-06-30

Similar Documents

Publication Publication Date Title
US9453050B2 (en) Compositions for treating glioma
Wen et al. A novel role of matrix metalloproteinase-8 in macrophage differentiation and polarization
US20130273057A1 (en) Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders
US8871205B2 (en) Methods and compositions for the treatment of immune disorders
EP3431498A1 (en) Treatment of fibrosis of the gastrointestinal tract with antibodies which prevent il-11:il-11ralpha interaction
US20180193382A1 (en) Methods of treating cancer, infectious disease, and autoimmune disease using cxc chemokines
CN102348796B (zh) 新型癌抗原eEF2
Li et al. Pathogenic Tconvs promote inflammatory macrophage polarization through GM‐CSF and exacerbate abdominal aortic aneurysm formation
JP5847590B2 (ja) 生体材料およびその使用
US20100266579A1 (en) Treatment of inflammatory diseases
CN102666877B (zh) 治疗神经病理性疼痛的组合物及方法
JP2017505763A (ja) 生物学的材料およびその治療用途
US9546366B2 (en) Replication factor C-40 (RFC40/RFC2) as a prognostic marker and target in estrogen positive and negative and triple negative breast cancer
CN106177953A (zh) Tlr3抑制剂在制备防治肿瘤转移产品中的应用
JP2016520570A (ja) Ａ型インフルエンザウイルス感染の治療又は予防に使用するためのｐａｒ−４アンタゴニスト
US9970012B2 (en) Replication factor C-40 (RFC40/RFC2) as a prognostic marker and target in estrogen positive and negative and triple negative breast cancer
SK8882002A3 (en) Human heparanase-related polypeptide and nucleic acid
KR101522729B1 (ko) 파골세포 융합의 새로운 바이오 마커인 piro
KR101699567B1 (ko) ＪｕｎＢ의 발현 또는 활성 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
JP7580739B2 (ja) オンコスタチンｍ受容体シグナリング制御による尿路結石の予防と治療
US20150273019A1 (en) Method of treating wounds
JP2024511569A (ja) 免疫増強剤
WO2022032592A1 (en) Interleukin-17d and cd93 as a new cytokine-receptor pair in the immune system
WO2022192528A1 (en) Gal3bp polypeptide compositions and methods for treatment of cancer and determining treatment responsiveness
WO2012052995A2 (en) Treatment and prevention of hepatocellular carcinoma with chemokine receptor modulators

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20171030

FZDE Discontinued

Effective date: 20210831